Autobio Diagnostics released its 2026 interim report, with overseas business revenue reaching 220 million yuan, a year-on-year increase of 40.13%. In the first half of the year, the company achieved revenue of 2.058 billion yuan and net profit attributable to the parent of 497 million yuan. Against the backdrop of pressure on the domestic in vitro diagnostics industry from centralized procurement and medical insurance payment reforms, the company has made overseas markets an important strategic direction. As of the first half of the year, Autobio Diagnostics' products have covered more than 120 countries and regions worldwide, obtained 678 EU CE certifications, established a subsidiary in Indonesia, and signed a memorandum of cooperation with a Vietnamese medical group. The company stated that in 2026 it will continue to increase overseas investment and seize opportunities in the global IVD sector.
Autobio Diagnostics Co LtdOverseas revenue grew 40% year-on-year, driven by expansion into 120+ countries and new partnerships.
